Pfizer, Astellas' Xtandi scores Bayer-matching win in extending prostate cancer patients' lives

Xtandi is the second drug to show an improvement in patients' overall survival in nonmetastatic castration-resistant prostate cancer. (Pfizer)

Pfizer and Astellas' Xtandi has been locked in a heated prostate cancer tussle with a challenger from Johnson & Johnson and, more recently, one from Bayer. One area where the pair was looking for a win? Showing Xtandi prolonged patients' lives––and new data has done just that.

Xtandi significantly extended patients' lives over standard-of-care hormone therapy in nonmetastatic castration-resistant prostate cancer, according to an overall survival analysis from the phase 3 Prosper trial released Tuesday. 

The newest survival data met the secondary endpoint for the Prosper trial, which helped Xtandi nab an FDA approval as an add-on to androgen deprivation therapy (ADT) in that hard-to-treat prostate cancer population back in July 2018. 

Sponsored by Lubrizol Life Science

[Webinar] Cannabinoid Formulation - from Farm to Pharma

Wednesday, June 24, 2020 | 12pm ET / 9am PT

A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.

RELATED: Bayer's Nubeqa scores key prostate cancer win in battle with Pfizer, J&J

With its overall survival data in hand—considered the gold standard when it comes to cancer trials—Pfizer and Astellas can help build Xtandi's case as the market leader in castration-resistant prostate cancer as the drug fends off challengers from Johnson & Johnson and Bayer. 

Last month, Bayer and Orion's Nubeqa actually beat Xtandi to the punch with trial data showing it extended patients' lives over ADT alone in the nonmetastatic setting. Despite being last to the party with a July 2019 approval from the FDA, those results left Xtandi and J&J's Erleada scrambling to catch up. 

Erleada, for its part, has made a run at matching OS data but has so far fallen short. 

At the European Society for Medical Oncology annual meeting in September, J&J unveiled that its Erleada-ADT pairing cut patients’ risk of death by 25% compared with a combo of ADT plus placebo. However, at that second interim analysis, the benefit wasn’t enough to cross the statistical significance bar.

RELATED: Pfizer, Astellas' Xtandi matches J&J's rival Erleada with new prostate cancer nod

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.